GLP-1 RECEPTOR AGONIST MARKET ANALYSIS

GLP-1 Receptor Agonist Market Size and Trends

Global GLP-1 receptor agonist market is estimated to be valued at USD 28.19 Bn in 2025 and is expected to reach USD 63.54 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 12.3% from 2025 to 2032.

To learn more about this report, Request sample copy

The market growth can be attributed to factors such as rising prevalence of type 2 diabetes and obesity across countries. Global GLP-1 receptor agonist market is expected to witness lucrative growth over the forecast period as increasing number of patients are opting for GLP-1 drugs due  to their greater efficacy and lesser side effects compared to conventional diabetes medications. Furthermore, rising launch of novel formulations such as long-acting therapies with dosing convenience can drive the market growth.

Rising prevalence of diabetes

Rising prevalence of diabetes across the globe can drive the global GLP-1 receptor agonist market growth. As per the International Diabetes Federation, approximately 537 million adults lived with diabetes in 2021, which is projected to increase to 783 million by 2045. This increased burden of diabetes cases boosts need for effective diabetes management. GLP-1 receptor agonists  is an efficacious therapeutic option for the treatment of type 2 diabetes. These work by stimulating the beta cells of the pancreas to release more insulin when blood sugar levels are high. This unique mechanism of action enables better glycemic control along with weight loss benefits. According to WHO, more than 60% of adults with diabetes are overweight, which further exaggerates insulin resistance. GLP-1 receptor agonists provide an advantage over other antidiabetic drugs by simultaneously managing blood sugar as well as weight of patients. GLP-1 receptor agonists have gained popularity due to their established efficacy and safety profile demonstrated via long term clinical trials. For example, as per the research published by Diabetes Care Journal in 2021, treatment with GLP-1 receptor agonist semaglutide led to statistically significant and clinically relevant reductions in HbA1c and body weight that were sustained for more than 2 years in patients with type 2 diabetes. Such decisive therapeutic benefits have accelerated the shift towards GLP-1 receptor agonists from traditional antidiabetic therapies.  Major pharmaceutical companies are also proactively launching affordable biosimilar versions of these drugs to increase accessibility in developing nations. For instance, in October 2023, American Diabetes Association Diabetes has emerged as the fastest-growing chronic disease globally and the costliest in the U.S. With over 37 million Americans affected, one in five are unaware about their condition. Each November, 116,500 Americans receive a diabetes diagnosis, with 23,500 people succumbing to related illnesses. The American Diabetes Association (ADA) urges awareness and action, offering resources to prevent, manage, and ultimately eradicate diabetes.